REC-1245 not checked
Recursion Pharmaceuticals Inc.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas
- Main trialPhase 1/2
- “This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.”In the company’s words, NCT06678659 on ClinicalTrials.gov
Other drugs for Unresectable
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Jul 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 19 NovCompletion date moved: 2028-10-30 to 2029-07 · ClinicalTrials.gov NCT06678659
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jul 2029 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026